When Databricks claimed to have cracked an age-old database problem, it came with a clear marketing message: "One data, zero compromises, zero copies." Inevitably, that led engineers to search for ...

Ingelheim, Germany - Boehringer Ingelheim today announced positive results from two global Phase III trials of its glucagon/GLP-1 dual agonist survodutide (BI 456906), SYNCHRONIZE-1 and ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...

In SYNCHRONIZE-1, survodutide achieved −12.2% to −13.0% weight loss at 76 weeks versus −5.4% with placebo, with ≥20% loss in 28.5% at 6.0 mg. MRI substudy data showed organ-selective effects: liver ...

Zealand Pharma announces Boehringer Ingelheim's survodutide Phase III trial showed targeted 34% visceral and 63% liver fat reduction, while minimizing lean mass loss in pre-specified analysis, ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...

News builds on previously announced positive topline results from SYNCHRONIZE-1 76-week trial, which met its primary endpoints and showed up to 16.6% weight loss with survodutide, a novel glucagon/GLP ...

Boehringer Ingelheim disclosed full Phase 3 data for survodutide at the American Diabetes Association's 2026 Scientific Sessions in New Orleans on Sunday, June 7, showing that nearly 1 in 5 patients ...

NEW ORLEANS — Survodutide, an investigational glucagon receptor/GLP-1 receptor dual agonist, produced significant weight loss along with reductions in visceral fat and liver fat in two phase 3 trials.

As of October 2025, the World Economic Outlook database and supporting documents will be accessible through the IMF Data portal. The World Economic Outlook (WEO) database is created during the ...